drugset / Trial / NCT00691145

Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis

NCT00691145

Phase 3 Completed 350 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the efficacy and safety of 0.1% and 0.03% Tacrolimus ointment for 12 months in adults with moderate to severe atopic dermatitis.

Timeline

Start
2002-10
Primary completion
2005-02
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.03 % Other
Subject Tacrolimus Small molecule 0.1 % Other

Indications